MOMS is proud to announce our partnership with BillionToOne, a genetic lab testing platform that accurately and efficiently detects and measures disease at the molecular level.
“We believe that applying engineering principles to biology will be transformative for medicine and make diagnostics much more powerful, accurate, and affordable,” explains Dr. Oguzhan Atay, CEO. “BillionToOne is excited to partner with MOMS and expand our reach to even more patients in need of highly precise DNA testing.”
About BillionToOne
BillionToOne is a precision diagnostics company that strives to make healthcare more affordable and in reach for the majority of individuals by offering powerful molecular diagnostic testing. Their team of engineers, scientists, and industry experts is committed to redefining healthcare with tools that quantify biology and help eliminate the fear of the unknown.
By counting single DNA molecules, BillionToOne creates diagnostics that measure DNA with 1000x more detail. These tests deliver extremely accurate and efficient results, reduce testing uncertainty, and give clinicians and patients the clarity needed to make more confident medical decisions.
Their UNITY™ test is the only prenatal, cell-free DNA test that screens the baby’s risk for:
- Cystic Fibrosis
- Spinal Muscular Atrophy
- Sickle Cell Disease
- Thalassemias
- Trisomy 21 (Down Syndrome)
- Trisomy 18 (Edwards Syndrome)
- Trisomy 13 (Patau Syndrome)
- Sex Chromosome Aneuploidy
The blood sample for this test is drawn from the mother’s arm, with no paternal test required. UNITY™ opens the door to safe, reliable, and affordable prenatal screening for all women.
They have also developed a groundbreaking COVID-19 test assay that was granted FDA Emergency Use Authorization. The qSanger-COVID-19 assay removes the costly and time-consuming step of RNA extraction and has the potential to unlock millions in daily COVID-19 testing capacity worldwide.
BillionToOne’s cancer liquid biopsy diagnostic test (coming soon) lowers the limit of detection for gene amplifications by 10x, enabling cancer to be detected sooner.
We are excited to have BillionToOne on the MOMS platform and are eager to join in their mission of making highly accurate diagnostic testing more accessible and affordable.
